Though I am barish on the stock, I would refrain from being so disrespctful of someone who has done somthing unmatched ever in the stock market.
For the past few days I guess only Chanos has been right, but anyone can be right over a week, month or a year. To be right over decades, well, that's Buffet and no one else.
The bearish sign was that despite Buffet saying they would buy more as IBM became "cheaper", they actually diid not buy any last Q.
I wish people kept these boards civil so that we could, for once, learn from one another!
Everyday MMS take a few stocks and bump them to the moon and a few days later dump them even harder.
The game is to learn which and when as no junior energy stock is worth holding onto -- buyout/takeover stories are nothing but BS in this environment
Do you want to see market manipulation?
Have a look at all those energy and metal stocks that went up altogether all of a sudden despite a huge down day and oil falling
I am wondering what the plural of Chinese is!
Is it "Chineses"?
I just wonder how many of you bashers are plain illiterate!
If you can't even remember the name nor the tcker of a Co, what credit would you expect for bashing them?
We all know it is down, has lots of debt, write-downs, hedges... and it may even go bankrupt, as may lots of other E&P Companies.
The difference here is that there is an owner and CEO with proven track record who has actually bought more shares.
I do not think anyone on this board or any of the analysts covering this stock can claim to have much better knowledge of the oil market and operational know-how than he does.
Now if you have something meaningful to say, other than a one-line bash-in-the wind, do share as I appreciate to learn something new!
Thanks for sharing your thoughts
Very pleasant to see there are still decent, objective people on these boards
IS FCX going bankrupt? Based on trading pattern, I guess you believe 99.9% of all miners should go banrupt!
They have been getting contracts in this awful environment, have enough funds to cover short term funding and unless they lie in their filings (which I highly doubt), they can weather this storm for at least another one to two years.
Now, do you hava any real numbers, facts... to back you or just throwing unfounded rumors to shake the tree?
If you do, it will be highly appreciated.
We are all in this to make money, up or down, no one cares - so share real stuff
Epratuzumab flunks two Phase 3 studies; Immunomedics plummets 42% premarket
Immunomedics (NASDAQ:IMMU) is off 42% premarket on robust volume in response to an announcement from collaboration partner UCB that two Phase 3 clinical trials evaluating IMMU's lead product candidate, Fast Track-tagged epratuzumab, in systemic lupus erythematosus (SLE) failed to achieve their primary efficacy endpoints. UCB secured the global rights to epratuzumab for non-cancer applications in May in a deal that paid IMMU $38M upfront.The two studies, EMBODY 1 and EMBODY 2, had the same primary endpoint of the percent of subjects meeting treatment response criteria at week 48 as measured by a combined response index called BILAG-based Combined Lupus Assessment. Both treatment arms failed to show a statistically significant increase in treatment effect compared to placebo.UCB's Chief Medical Officer Professor Iris Loew-Friedrich, M.D., says, "Although we are disappointed with the results from the Phase 3 program, our commitment to the lupus community remains." She offers no clarity on the fate of epratuzumab, however.Epratuzumab is a humanized monoclonal antibody that targets CD22, a protein found on the surface of immune system white blood cells called B-lymphocytes. Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system. Other SLE therapies destroy B-cells which compromises the immune system.
Thanks for sharing
I also fund the following:
Maxim mentioned it's "gaining dollar content per unit" in a next-gen smartphone from its mobile client (Samsung) for which orders are expected to ramp in FQ1 - that's likely a reference to the Galaxy Note 5.
Now the whole upside is rather suspect with regards to what happened to Apple: Mkt seems to be worried about Apple's China momentum growth, which should equally apply to all other smartphone manufacturers. And for that matter, everyone knows Samsung has been lagging for quite some time.
Also, SWKS provided far superior numbers and projections but the stock still went down! In what universe is MXIM is a better run Co or stock than SWKS? Or for that matter, why did CRUS have such a fantastic day (fantastic results though) despite being a far more limited Apple supplier than SWKS or AVGO? I simply guess MM pick and choose as they wish. If Apple future sales are a real concern, then why would any of their suppliers go up? It seems to be a matter of double standards!
So other than an irrational bump on such a down day, I don't see MXIM being able to hold on to those gains especially in light of the fact that the Mkt seems to be far more concerned about Rev growth rather than the bottom line, otherwise why would AMZN, NFLX, TSLA and a whole bunch of cybersecurity stocks trade at such rich multiples while hardly making any money?
I posted after earnings that these people would start buying again at $160, at which point I bought some Aug 165 calls.
They are the only ones holding PPS above $160 and they will buy more any time it goes below.
Their average price is now around $174 and they will dump it just above that - forget all their BS about value, adaptability, LT investment whatnot; they are simply getting desparate.
This market is all about Rev growth; profits seem not to matter. Just look at some software companies reports this evening, and yeah, AMZN made a few cents of profit after 20 years and it is up....20%
GLTA, hope you all make tons of money